Eidos Therapeutics Inc (EIDX) Given Consensus Recommendation of “Buy” by Analysts

Share on StockTwits

Eidos Therapeutics Inc (NASDAQ:EIDX) has been assigned a consensus broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and two have given a strong buy rating to the company.

Brokerages have set a twelve-month consensus price objective of $29.67 for the company and are expecting that the company will post ($0.35) EPS for the current quarter, according to Zacks. Zacks has also given Eidos Therapeutics an industry rank of 98 out of 255 based on the ratings given to its competitors.

A number of brokerages recently weighed in on EIDX. JPMorgan Chase & Co. began coverage on shares of Eidos Therapeutics in a research note on Monday, July 16th. They issued an “overweight” rating and a $36.00 price target on the stock. Barclays began coverage on shares of Eidos Therapeutics in a research note on Monday, July 16th. They issued an “overweight” rating and a $32.00 price target on the stock. Bank of America began coverage on shares of Eidos Therapeutics in a research note on Monday, July 16th. They issued a “neutral” rating and a $24.00 price target on the stock. Finally, Zacks Investment Research lowered shares of Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday.

NASDAQ:EIDX opened at $11.07 on Tuesday. Eidos Therapeutics has a one year low of $11.00 and a one year high of $24.75.

Eidos Therapeutics (NASDAQ:EIDX) last posted its earnings results on Tuesday, August 7th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($1.15). equities research analysts forecast that Eidos Therapeutics will post -2.09 EPS for the current year.

Institutional investors have recently modified their holdings of the stock. Dean Capital Investments Management LLC acquired a new stake in Eidos Therapeutics in the 2nd quarter valued at about $528,000. Board of Trustees of The Leland Stanford Junior University acquired a new stake in Eidos Therapeutics in the 2nd quarter valued at about $3,642,000. BlackRock Inc. acquired a new stake in Eidos Therapeutics in the 2nd quarter valued at about $3,051,000. Janus Henderson Group PLC acquired a new stake in Eidos Therapeutics in the 2nd quarter valued at about $6,511,000. Finally, Tiverton Asset Management LLC acquired a new stake in Eidos Therapeutics in the 2nd quarter valued at about $163,000. 22.93% of the stock is currently owned by hedge funds and other institutional investors.

About Eidos Therapeutics

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

See Also: Understanding Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on Eidos Therapeutics (EIDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.